Fig. 3: Simulated BRR of ten VPops across increasing dose schedules. | npj Systems Biology and Applications

Fig. 3: Simulated BRR of ten VPops across increasing dose schedules.

From: Leveraging quantitative systems pharmacology modeling for elranatamab regimen optimization in relapsed or refractory multiple myeloma

Fig. 3

Explored doses ranged from 16 mg to 152 mg QW. A 76 mg Q2W regimen was also simulated and resulted in very similar efficacy as measured by the BRR of 44 mg QW. Error bars represent 95% confidence intervals. a BRR stratified by baseline sBCMA levels. The model suggests that the optimal regimen for patients with low sBCMA levels (blue) and high sBCMA levels (red) is 76 mg Q2W (BRR, 81%) and 152 mg QW (BRR, 53%), respectively. b For all virtual patients, simulated BRR ranged from 39% to 68%, and there was no significant gain in efficacy from 76 mg QW (68%) to 152 mg QW (66%). BRR biochemical response rate, QW once weekly, Q2W every 2 weeks, sBCMA soluble B-cell maturation antigen, VPop virtual population.

Back to article page